Trials / Withdrawn
WithdrawnNCT02082197
An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men
A Multicenter, Open-Label, Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-study with a 26 week open label treatment period followed by an optional 26 week open label extension. The total treatment period will be 52 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-SLV176 | ABT-SLV176 administered daily |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2014-03-10
- Last updated
- 2014-06-02
Locations
42 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02082197. Inclusion in this directory is not an endorsement.